Ligand id: 5660

Name: motesanib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 78.94
Molecular weight 373.19
XLogP 2.99
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Motesanib has undergone many clinical trials to determine its potential as a cancer therapy. It progressed to Phase 3 evaluation in NSCLC but these studies were terminated as they failed to meet the predetermined primary endpoint. Click here to link to's full list of motesanib trials.
Mechanism Of Action and Pharmacodynamic Effects
Inhibitis vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis and may therefore reduce the vascularisation which underpins and supports tumour development and growth.